C12N 2830/42
Being an intron or intervening sequence for splicing and/or stability of rna
Official title: being an intron or intervening sequence for splicing and/or stability of RNA
C12N2830/42 (Being an intron or intervening sequence for splicing and/or stability of rna) appears on 533 US grants and 853 published applications in this corpus.
Search patents in C12N- Granted patents
- 533
- Published applications
- 853
- Assignees
- 478
- Inventors
- 1,660
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 3 | 0 |
| 1994 | 1 | 0 |
| 1995 | 3 | 0 |
| 1996 | 11 | 0 |
| 1997 | 22 | 0 |
| 1998 | 21 | 0 |
| 1999 | 21 | 0 |
| 2000 | 29 | 0 |
| 2001 | 19 | 8 |
| 2002 | 28 | 37 |
| 2003 | 18 | 73 |
| 2004 | 16 | 50 |
| 2005 | 10 | 38 |
| 2006 | 20 | 43 |
| 2007 | 17 | 16 |
| 2008 | 9 | 18 |
| 2009 | 17 | 22 |
| 2010 | 20 | 19 |
| 2011 | 11 | 10 |
| 2012 | 9 | 12 |
| 2013 | 9 | 10 |
| 2014 | 11 | 18 |
| 2015 | 6 | 14 |
| 2016 | 13 | 16 |
| 2017 | 13 | 22 |
| 2018 | 18 | 25 |
| 2019 | 16 | 25 |
| 2020 | 14 | 30 |
| 2021 | 15 | 42 |
| 2022 | 14 | 46 |
| 2023 | 22 | 67 |
| 2024 | 25 | 77 |
| 2025 | 26 | 68 |
| 2026 | 25 | 47 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions useful for treatment of Charcot-Marie-Tooth disease6 Oct 2026US 12,753,419 B2The Trustees of the University of Pennsylvania
- Integration of nucleic acid constructs into eukaryotic cells with a transposase from oryzias22 Sep 2026US 12,742,171 B2Dna Twopointo Inc.
- Methods of treating hearing loss using a secreted target protein11 Aug 2026US 12,703,874 B2Akouos, Inc.
- DNA origami encoding for gene expression and contransfection4 Aug 2026US 12,698,510 B2Technische Universität München
- Methods and compositions for treating glycogen storage diseases28 Jul 2026US 12,692,512 B2Ultragenyx Pharmaceutical Inc.
- Targeting gpatch8 for treating sf3b1-mutant cancers8 Oct 2026US 2026/0306672 A1Fred Hutchinson Cancer Center
- Retroviral vectors8 Oct 2026US 2026/0308619 A1UCL Business PLC
- Treatment of multiple sclerosis using nt-3 gene therapy1 Oct 2026US 2026/0295091 A1Research Institute At Nationwide Children's Hospital
- Novel internal ribosome entry site (ires) and intron sequences1 Oct 2026US 2026/0297579 A1Ginkgo Bioworks, Inc.
- Novel Fragile X Constructs1 Oct 2026US 2026/0297623 A1uniQure biopharma B.V.
Most cited
By later US patents
- Genetic constructs for delaying or repressing the expression of a target gene369US 6,573,099 B2Benitec Australia Limited · 2003
- Packaging systems for human recombinant adenovirus to be used in gene therapy267US 5,994,128 AIntrogene B.V. · 1999
- Transgenic bovine266US 5,741,957 APharming B.V. · 1998
- DNA sequences to target proteins to the mammary gland for efficient secretion214US 5,304,489 AGenPharm International, Inc. · 1994
- Eukaryotic layered vector initiation systems204US 5,814,482 A1998